Alpha 1-protease inhibitor moderates human neutrophil elastase-induced emphysema and secretory cell metaplasia in hamsters.
A study was undertaken to determine whether emphysema and airway secretory cell metaplasia, induced in hamsters by intratracheal treatment with human neutrophil elastase (HNE), could be moderated by pretreatment with human alpha 1-protease inhibitor (API). API (4.9 mg) was given intratracheally to hamsters 1 h before 0.3 mg HNE. Eight weeks later, lung volumes and pressure-volume relationships were measured in the anaesthetized animals. Mean linear intercepts and secretory cell indices were measured in lung sections. API given 1 h before HNE moderated the development of bronchial secretory cell metaplasia. The severity of emphysema was reduced by 75%. Clearance studies indicated that 80% of the functional activity of instilled API could be lavaged from the lungs after 1 h, indicating a 4 h half-life in the lavageable compartment of the lungs. We calculate that for 50% protection from emphysema the molar ratio of lavageable API to HNE at the time of HNE instillation was 4.8 as compared with 0.78 for 50% inhibition of elastolytic activity in vitro, indicating that API is only 16% as efficient in vivo as compared with its in vitro HNE inhibitory effectiveness. Nevertheless, we conclude that human API given intratracheally is efficacious against HNE-induced emphysema and secretory cell metaplasia.
Stone
P J
PJ
Pulmonary Center, Boston University School of Medicine, MA 02118.
Lucey
E C
EC
Virca
G D
GD
Christensen
T G
TG
Breuer
R
R
Snider
G L
GL
D000818:Animals; D001980:Bronchi / Q000473:pathology*; D006224:Cricetinae; D006801:Humans; D019272:Leukocyte Elastase; D008297:Male; D008679:Metaplasia; D010196:Pancreatic Elastase / Q000633:toxicity*; D011292:Premedication; D011656:Pulmonary Emphysema / Q000139:chemically induced / Q000188:drug therapy*; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*
D000515:alpha 1-Antitrypsin; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase